Literature DB >> 11733534

Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells.

Cheng Song1, George Perides, Ya Fang Liu.   

Abstract

We reported previously that normal Huntingtin is associated with epidermal growth factor receptor (EGF) signaling complex (Liu, Y. F., Deth, C. R., and Devys, D. (1997) J. Biol. Chem. 272, 8121-8124). To investigate the potential role of normal and polyglutamine-expanded Huntingtin in the regulation of growth factor receptor-mediated cellular signaling and biological function, we stably transfected full-length Huntingtin containing 16, 48, or 89 polyglutamine repeats into PC12 cells where cellular signaling mechanisms, mediated by nerve growth factor (NGF) or EGF receptors, are well characterized. Expression of polyglutamine-expanded Huntingtin, but not normal Huntingtin, leads to a dramatic morphological change. In clones carrying the mutated Huntingtin, both NGF and EGF receptor-mediated activation of mitogen-activated protein kinase, c-Jun N-terminal kinase, and Akt are significantly attenuated, and NGF receptor-mediated neurite outgrowth is blocked. Co-immunoprecipitation studies show that the associations of NGF or EGF receptors with growth factor receptor-binding protein 2 (Grb2) and phosphoinositide 3-kinase are significantly inhibited. NGF-induced tyrosine phosphorylation of NGF receptors (TrkA) is also consistently suppressed. Our data demonstrate that polyglutamine-expanded Huntingtin disrupts cellular signaling mediated by both EGF and NGF receptors in PC12 cells. It is known that Huntington's disease patients exhibit an extremely low incidence of a variety of cancers and are deficient in glucose metabolism. Thus, our results may reflect an important molecular mechanism for the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733534     DOI: 10.1074/jbc.M110338200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Inhibitors of metabolism rescue cell death in Huntington's disease models.

Authors:  Hemant Varma; Richard Cheng; Cindy Voisine; Anne C Hart; Brent R Stockwell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

2.  EGF Treatment Improves Motor Behavior and Cortical GABAergic Function in the R6/2 Mouse Model of Huntington's Disease.

Authors:  Felecia M Marottoli; Mercedes Priego; Eden Flores-Barrera; Rohan Pisharody; Steve Zaldua; Kelly D Fan; Giri K Ekkurthi; Scott T Brady; Gerardo A Morfini; Kuei Y Tseng; Leon M Tai
Journal:  Mol Neurobiol       Date:  2019-05-19       Impact factor: 5.590

Review 3.  Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.

Authors:  Masahiro Waza; Hiroaki Adachi; Masahisa Katsuno; Makoto Minamiyama; Fumiaki Tanaka; Manabu Doyu; Gen Sobue
Journal:  J Mol Med (Berl)       Date:  2006-06-02       Impact factor: 4.599

4.  ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease.

Authors:  Pamela Maher; Richard Dargusch; Laszlo Bodai; Paul E Gerard; Judith M Purcell; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2010-10-15       Impact factor: 6.150

5.  Cdc42-interacting protein 4 binds to huntingtin: neuropathologic and biological evidence for a role in Huntington's disease.

Authors:  Sébastien Holbert; Alpaslan Dedeoglu; Sandrine Humbert; Frédéric Saudou; Robert J Ferrante; Christian Néri
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

6.  Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.

Authors:  Melissa R Sarantos; Theodora Papanikolaou; Lisa M Ellerby; Robert E Hughes
Journal:  J Huntingtons Dis       Date:  2012

7.  The brain uncoupling protein UCP4 attenuates mitochondrial toxin-induced cell death: role of extracellular signal-regulated kinases in bioenergetics adaptation and cell survival.

Authors:  Zelan Wei; Srinivasulu Chigurupati; Pamela Bagsiyao; Alicia Henriquez; Sic L Chan
Journal:  Neurotox Res       Date:  2009-03-25       Impact factor: 3.911

Review 8.  Perturbed signal transduction in neurodegenerative disorders involving aberrant protein aggregation.

Authors:  Mark P Mattson; Michael Sherman
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

9.  The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling.

Authors:  Cristovão Moreira Sousa; John Russel McGuire; Morgane Sonia Thion; David Gentien; Pierre de la Grange; Sophie Tezenas du Montcel; Anne Vincent-Salomon; Alexandra Durr; Sandrine Humbert
Journal:  EMBO Mol Med       Date:  2013-01-09       Impact factor: 12.137

10.  Huntington's disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads database.

Authors:  Ravi Kiran Reddy Kalathur; Miguel A Hernández-Prieto; Matthias E Futschik
Journal:  BMC Neurol       Date:  2012-06-28       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.